WASHINGTON (Legal Newsline) – Pharmaceutical company Actavis confirmed Thursday that the U.S. Court of Appeals for the Federal Circuit has upheld a ruling finding its patent for a popular low-estrogen birth control pill to be valid.
The Federal Circuit issued its decision Wednesday.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.